Subscribe Now!

Understanding Pharma Growth from various important corners

“Practitioners’ Insights: Understanding Pharma”


Shuchi.P.Nahar

India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50% of global demand for various vaccines, 
40% of generic demand in the US and 25 % of all medicine in UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 % of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are by Indian pharmaceutical firms.

The global pharmaceutical market is expected to exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. The key drivers of growth will continue to be the United States and emerging markets with 4−7% and 5–8% compound annual growth, respectively.

The global outlook for medicine use and spending affects the prospects of life sciences companies, insurers and the health of populations around the world.
Patent/ Innovators : A patent is a type of intellectual property right that provides protection over any novel invention and also, gives the exclusive right to sell, use, create and/or manufacture the patented product.



As new and improved drugs are being introduced every year in the market, drug or pharmaceutical patents have become particularly important as these drugs helps to generate a significant amount of revenue for their commercial benefits. The pharmaceutical sector is an area in which innovation impacts the bottom line of the drug manufacturers who focus on research and development of a new drug and incur huge costs in doing so, where there is neither a guarantee nor an assurance that their research product shall survive various testing stages and will commercially thrive if released in the market.
Branded Drugs : Branded medicines may be the original medicine developed by a company or several companies may make the same generic medicine, to which each company gives its own brand name.

Generics : generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is believed to be equivalent in performance. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulationexcipients, color, taste, and packaging.

OTC : Over-the-counter (OTCdrugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional,as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription. In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products.

Biosimilars : biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines.

Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires.Reference to the innovator product is an integral component of the approval.

Biologics : Biologics are a particular genre of drugs whose active ingredients are sourced from living organisms that have been specifically modified to produce the desired molecules. Unlike small molecules, which are usually produced by chemical synthesis, biologic drugs are giant molecules, typically proteins, which are hundreds of times the size of a conventional drug molecule. 

Such large proteins cannot be manufactured through chemical synthesis, but are produced inside animal cells or micro-organisms such as bacteria and viruses cultivated in large fermenters, or sometimes even in specially modified (or ‘genetically engineered’) plants or animals (and extracted from the leaves of the plant or milk of the animal).

Overview of the sector

The global pharmaceutical market will exceed $1.5 trillion by 2023 growing at a 3−6% compound annual growth rate over the next five years. The key drivers of growth will continue to be the United States and pharmerging markets with 4−7% and 5–8% compound annual growth, respectively. In the United States, overall spending growth is driven by a range of factors including new product uptake and brand pricing, while it is offset by patent expiries and generics. 

Medicine spending in Japan totaled $86 billion in 2018, however spending on medicines is expected to decline by -3 to 0% through 2023, largely because of exchange rates and the continued uptake of generics. In Europe, cost-containment measures and less growth from new products contribute to slower growth of 1−4%, compared to the 4.7% compound annual growth seen over the past five years. 

Pharmaceutical spending in China reached $137 billion in 2018 and is expected to reach $140−170 billion by 2023, but its growth is likely to slow to 3−6%. 


New products and losses of exclusivity will continue to drive similar dynamics across developed markets, while product mix will continue to shift to specialty and orphan products. An average of 54 new active substance (NAS) launches per year are expected over the next five years and two-thirds of launches will be specialty products, lifting specialty share of spending to near 50% by 2023 in most developed markets. 

At the same time, the impact of losses of exclusivity in developed markets is expected to be $121 billion between 2019 and 2023, with 80% of this impact, or $95 billion, in the United States. 

By 2023, biosimilar competition in the biologics market will be nearly three-times larger than it is today. This will result in approximately $160 billion in lower spending over the next five years than it would have if biosimilars did not enter the market.

Changing Landscapes

Consolidation in the sector can be observed in the coming years based on the valuations , companies in coming years will be focusing on therapies and specialty segment. As healthcare cost will be on increasing trend based on need of maintenance of high quality of drugs , facilities will be improving as government will be shifting their focus on faster approval of generic / biosimilars. 

As per government's future plan to focus on local brands , local manufacturing players will be given more boost in coming years which will lead to reduction of cost , local manufacturing will help in generating employment in the country. 

PM Narendra Modi in his latest speech mentioned about be "vocal for local " that clearly signifies the importance of using the local brands and giving initaitaives to local manufacturers.

Technology transfer (acquisition or JV route) to have presence in the countries. Many countries consider secondary packing, sourcing material locally also as local manufacturing it will surely challenge the trust perspective of indian people but will lead to government benefits , shorter lead time to markets.


Registration timelines will increase i.e 3/6 months to 3 - 4 years Leverage of developed country dossiers waivers timelines reduced by half) the upcoming pharma trend will observe faster acceptance of Generics in the markets.

Switching from Rx to OTC (permissible in certain drugs ) Medical Officer of Health will be in acceptance of such type of switching of drugs. No price cap, entry in new channel for distribution, Advertising/Marketing. Government will focus on increase in production of medicine in manufactured India and will promote marketing , distribution in India .

Quality Growth Uptick in licensing of Dossiers : Now the dossier that will be available will be of high quality dossiers and the entry time of drugs to enter the markets will be faster than before.

IP landscape is going to be more challenging for the companies.  Existing Patents will strengthen and further the Patent strength Generics will be seen to move at more faster pace. 

Pricing in reimbursed markets , the markets will be seen with a reasonable pricing policies with reference to pricing .

Reimbursement will be restricted to lowest priced generic drug (balance to be borne by patient OPE) . 

More drugs are now included in Essential Drug List Business feasibility, companies opting out of low price countries Business of larger company may be hived off from low priced markets and Illegal import activity. 

Healthy pipeline of differentiated molecules are observed in the Indian companies.  Company Budget is also been increasing looking at the opportunities bestowed by Indian government for being local manufacturers. Co’s with Specialty pipeline for future (low competition) would see higher valuations.

Contract Research/Manufacturing CRO / CMO is the developing market . Company basically dealing in CRAMS,CDMO,CRO are Expected to see rapid growth as demands for research and outsourcing of manufacturing , research bu the front-end companies will be solely dependent on these companies.

Changes in drug packing serialization, harmonization, transport temperature etc such type of improvements in the packing and marketing of the products can be expected from the Indian players. 

Higher cost Maintaining drug quality, enhanced tracking for recalls, cost efficiency as Indian companies will be motivated to expand as they have to maintain the product quality.
Packaging , marketing and advertising will be upto the mark of foreign companies to build the strong base in home country. 

Consolidation is the key 

In coming years handshakes with the big brands will be common. This type of consolidation will help the pharma companies to get their footholds not only in India but cater the markets abroad , getting excess to their markets , technical know how etc.

Growth will come from..


  • Novel therapies Personalised medicines, regenerative medicine
  • Biological drugs
  • New Drug delivery devices/mechanisms Delivering drug at controlled rate, slow
  • Delivery, targeted delivery of drug
  • Private insurance Share to increase
  • Automation at manufacturing plants, New manufacturing technology (cheaper
  • and faster)
  • Orphan drugs expected contribution in Rx drugs by 2024
  • Patient engagement
  • Embracing Technology DTx digital medicines, etc
  • CMO CRO


Current scenario

Companies continue to provide digital and internet based educational materials to physicians.
New features include online drug refills, direct to patient, enhancing face to face interactions with physicians, online pharmacies.

Challenge: change in physician behavior (limited time and history of tech usage)
Digital Therapeutics (DTx)
Evidence based software product that delivers a clinical intervention, used standalone or in combination with drug.

Usage of AI for interpretation
Enable doctors automate routine aspects. 
Essentially to help the more informed patient to be in control.
Clinicians can prescribe them standalone or in combination with prescription drugs. 
Healthcare providers and payers are embracing DTx. 

In US, the Department of Health and Human Services has been reimbursing digital therapeutic programs for administering the Diabetes Prevention Program since 2016.

Examples: 
Standalone uses for pain management, mental health, cognitive behavior therapies.
When combined with drugs (apps that track sensors on asthma inhalers or apps used in concert with glucose monitors), can deliver interventions that improve a range of patient benefits.

Total pharma market 35 bn (exports 15 billion and domestic 20 billion)
India Supplies 50-60 of the global vaccines demand (including ARVs) and 25 of all the medicines consumed in the UK respectively.

Indian drugs account for around 30 %(by volume) and about 10 %(by value) in the US 70-80 billion US generics market.

India has second highest number of FDA approved manufacturing facilities. Healthcare sector witnessed private equity of total US 11 billion with 27 deals in first half of 2019.

Manufacturing hubs in Baddi, Gujarat, Andhra Pradesh and Goa, India have started manufacturing (key challenge in terms of labor and potential shortage of RM).

70% of India's imports totaling 2.4 billion of APIs comes from China.C hina currently has a significant edge over India in API manufacturing low utility cost, low interest rate loans etc.

India has identified and prioritized production of 53% of raw materials and APIs as part of its "China plus one" policy to fill in supply gaps of affordable medicines, plan to invest 1.3 billion in domestic pharmaceutical products. 

Challenges

Pricing Jan Aushadhis, doctors prescribe generic name, Price control. Essential medicines, DPCO useful medicines, etc. 

In 2019 about 19 plants received official action indicated status and warning letters from FDA.

Overall pharma industry will continue to see increase in cost maintenance of margins through change in product mix and cost control required.

Companies that will see growth


  • Well invested in technology. 
  • Strong pipeline under development (along with filings done in past where approvals are expected). 
  • Investments in specialty molecules (with track record of successful conversion to commercialization)
  • Low leverage. 
  • Geographically diversified. 
  • Strong branded portfolio. 

Companies with a difficult future


  • Tender business dependence
  • Revenue dependence on countries with severe strain (high debt, low growth, resource dependent
  • (oil)
  • Weak portfolio (generic generic)
  • Lag in Operational efficiencies (Scale to enable negotiation, backward integration)
  • Non adoption of technology (eg;DTx)

My Key Takeaways:
Medicine spending in India is projected to grow 9-12 % over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.
Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.
India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US$ 100 billion by 2025.

Companies having their major business in CDMO , CRAMS , CDO will have a bright future.
The Indian government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. 

In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.
Sources: 
 IQVIA: The global use of medicine in 2019 and Outlook to 2023
Digital Therapeutics: pharma’s threat or opportunity, eye for pharma
EvaluatePharma® November 2019
IQVIA: The global use of medicine in 2019 and Outlook to 2023 
IBEF
Coherent market insights
 Bloomberg


Disclaimer : This report is wholly based on my understanding and my knowledge gained during the webinar held on 9th May 2020. The notes that will be shared here will be just for knowledge purpose. All the points covered here are the points I fathom during the webinar and have prepared a small note over that.

 All Credits to: CFA society India
Bharat Binyani , CFA Director ( Business Head)  at Cipla
Raunak Onkar  Co-Fund Manager, Head of the Research Team at PPFAS

                                                   SHUCHI.P.NAHAR

Comments

  1. Shuchi very informative article. It would be very helpful if you could attempt and create heat map of Indian pharma companies based on which markets they are focused i.e Branded generics, Generic Generics, Biosimilar and Biologics. Additionally if you could also rank them based on parameters listed in "Companies that will see growth" would provide holistics picture. Just a suggestion.

    ReplyDelete
  2. Looking for the top and best pharmaceutical companies in and across India? Alde bazaar can help you with all your needs.


    top pharma companies in world
    top indian pharmaceutical companies

    ReplyDelete
  3. Really informative post , thanks for informative post about medicine and its related business , farma business related info etc.
    need to buy generic medicine online like buy modalert 100mg online or buy tapentadol 100mg online in united states.

    ReplyDelete
  4. Nice blog to learn about Wholesale and Distribution .

    Thanks for sharing.

    ReplyDelete
  5. Thank you for sharing this article. I strongly suggest synerheal collagen particle wound dressing is the best solution for burn treatment.

    ReplyDelete
  6. Thankyou for sharing this article. From this blog i know about how to care about wounds by using synerheal collagen particle wound dressing.

    ReplyDelete
  7. Thank you for sharing this article. From this it is possible to learn about the effects of injury and the methods of repairing them.
    seeskin ultrathin collagen sheet

    ReplyDelete
  8. This comment has been removed by the author.

    ReplyDelete
  9. Due to this pandemic and extended lockdown mobile app development is a popular trend in health system. Telehealth app services help people to cope with various healthcare problems anytime and anywhere.

    ReplyDelete
  10. Nice Blog. Really your content is so helpful. Dear all please visit on Thedaic.com, If you are looking for pharmaceutical market research companies.

    ReplyDelete
  11. Injury care is unique in the medical field. If the wounds in our body are not properly maintained the consequences will be much worse. Take care about your wounds by synerheal collagen particle wound dressing.
    seeskin p collagen particle dressing

    ReplyDelete
  12. The complete patient, not just the wound, must be assessed for successful treatment of severe wounds.
    aquacel ag extra hydrofiber dressing
    buy medicine online in india

    ReplyDelete
  13. The way a scar looks is often determined by how effectively the wound heals. While scars from surgery or over joints such as the knees and elbows are difficult to avoid, scars from minor cuts and scrapes can be reduced in appearance by treating the wound appropriately at home.
    synersol ag nanocrystalline silver gel
    duoderm extra thin by convatec

    ReplyDelete
  14. Thanks for sharing such a nice blog about medical equipment Kidney tray is used to keep surgical instruments and dressing for sterilization. The product can also be made from 0.6mm S.S sheet to 0.8mm S.S sheet as per customer requirement with a reasonable minimum order. Lifeclave offers a variety of equipment and tools used for Anthropometric measurement and growth monitoring. The Height scale measurements are reliable and give a correct assessment of the nutritional status of individuals.

    ReplyDelete
  15. Injuriecollagen particles wound dressings are usually divided into small and large. Small wounds heal easily Thermal needs doctor's help to maintain large wounds. Doctors use collagen sheets to repair the wound by bandaging.

    ReplyDelete
  16. nice information share by you. this is very valuable post Well Care Meds

    ReplyDelete
  17. Nice blog post !! Pharma Franchisee India is the most trusted b2b pharmaceutical marketplace where you will find the top PCD Pharma Franchise companies for your PCD Pharma Franchise Business in India. The associated at this portal provide you with best quality pharma products.

    ReplyDelete
    Replies
    1. Derma Medicine Company is a trusted Pharma Company for the Dermatology range. We offer the Derma cosmetic companies in india Derma Franchise Company at pan India level. This is the best Derma PCD Pharma Franchise company that provide high quality range of Derma Products.

      Delete
  18. Thank so so much for this info. I just started a new blog from the scratch and hopping i will soon become a blogger like you.


    Pharma PCD Franchise Company
    PCD Pharma Franchise

    ReplyDelete
  19. Nice Piece of Content. To add onto it, the COVID-19 pandemic has taught us that the pharmaceutical industry plays a critical role in ensuring a patient-centered future. It constantly develops new drugs while exploring and finding new ways to customize medicines. India's drug manufacturers are among the world's largest suppliers of generic drugs.

    ReplyDelete
  20. Thanks for sharing us this brief information about buy generic medicine online, I would love to appreciate the way you have explained about buy generic medicine online. To know more about the usage, benefits and more about buy generic medicine online visit our website.

    ReplyDelete
  21. Thank you for sharing this Article Buy Medicine Online in India from the trusted Indian Online Pharmacy MetroMedi.com Online Medicine shopping with Cash on Delivery. 100% Original Products!

    ReplyDelete
  22. Thank you For sharing this blog. Check out Hydrogel used for removal of dead skin cells.

    ReplyDelete
  23. I am very impressed with your post because this post is very beneficial for me and provide a new knowledge to me.

    Advantages of Working with PCD Franchise Company

    ReplyDelete
  24. Simply wanna comment that you have a very decent website, I enjoy the style it actually stands out.

    Contract Manufacturing
    Third Party Manufacturing

    ReplyDelete
  25. Nice and informative blog! Find the most useful and recommended ways to buy women’s health medicines online and add them to their routine to receive the best results.
    If you want to Buy Women’s Health Medicines Online then you can click here.
    Thanks for sharing.

    ReplyDelete
  26. Thank you for this wonderful post. It is very informative and useful. I would like to share something here too.

    Top 10 Pharma Franchise Companies in India

    ReplyDelete
  27. thank you for sharing this blog. Synerheal particles for undermined/deep cavity and irregular surface wounds

    ReplyDelete
  28. Great post. Thanks for one marvelous posting! I enjoyed reading it. The information was very useful.

    Top PCD Pharma Franchise Companies in India

    ReplyDelete
  29. Thanks for sharing the nice blog. Pharmacy management software for your business .
    Occucare provides wide range of occupational health software for you.

    ReplyDelete
  30. Thank You for sharing this article. Synersol AG Gel - Nano Crystalline Silver is o protect the wound from bacterial colonization and maintaining a moist wound environment that is conducive to healing.

    ReplyDelete
  31. Careprost (With Brush) is an eye drop remedy that is powerful for both treating hypotrichosis and Glaucoma. It includes Bimatoprost Ophthalmic Solution 0.03%, which reduces eye pressure.
    Order Now :https://www.mylovedose.com/careprost-with-brush/
    Email : info@mylovedose.com
    Careprost Eye Drop With Brush
    Buy Careprost Eye Drop

    ReplyDelete
  32. Thank you for sharing this article. Colldrez D treatment for burns is a sterile, translucent, flexible dressing, designed to heal partial thickness burns, bed sores and skin transplants.

    ReplyDelete
  33. Thank you for sharing this blog. Seeskin AB Medicated particle Promotes healthy granulation in infected deep wounds for early grafting.

    ReplyDelete
  34. Very interesting blog post thanks for sharing with us. I really enjoyed reading it. The information was very useful. Try to post this kind of useful content in blog posts. I appreciated your work. Thank you.
    Trade Maantra | Pharma Franchise | Third Party Pharma Manufacturer | PCD Pharma

    ReplyDelete
  35. your blog is really amazing keep sharing this kind of useful information with us and check out our web portal Etisalat Yellowpages UAE for Medicine Suppliers

    ReplyDelete
  36. I saw you have unique knowledge of Pharma Products. Thanks for sharing such kind of information with us. VIT-Shield | VIT-Shield Medicines | VIT-Shield Ashwagandha 50mg tablets

    ReplyDelete
  37. your blog is really amazing keep sharing this kind of useful information with us and check out our web portal Etisalat Yellowpages UAE for pharmaceutical suppliers

    ReplyDelete
  38. According to the available information, the pharma exports from India are heavily dominated by generic drugs. These drugs manufactured by the top pharmaceutical manufacturing companies in India constitute nearly 70% of the global market.

    ReplyDelete
  39. We are pleased by the details you have posted on your blog, and I have enjoyed reading this information for future reference. Contribute a great deal! Learn something about Ayurved Avail Ayurvedico – Avail Healthcare

    ReplyDelete
  40. This comment has been removed by the author.

    ReplyDelete
  41. Such a great Information !!!

    Want to know or buy generic medicine online Visit Cenforce – 100mg (Generic Viagra )

    ReplyDelete
  42. Your Blog is really so interesting and they way you mentioned each and everything is really so perfect.

    Online Weight Loss Medication

    ReplyDelete
  43. Thanks for the commenting, opportunity please do follow our store for best generic medicines https://securepharmaonline.com/which-is-better-viagra-or-cialis.aspx

    ReplyDelete
  44. There are around 3,000 pharma companies in India. These companies own 10,500 manufacturing facilities for making Pharmaceutical Products in India.

    ReplyDelete
  45. With a detailed information about pharma industry you have made this post really engaging and interesting, for the students this is a guide for any reference. Generic Viagra Online.

    ReplyDelete
  46. Thank you for sharing this blog. FIX Plug dental Resorbable collagen wound dressing products

    ReplyDelete
  47. Your Blog is really so interesting and they way you mentioned each and everything is really so perfect.

    Visit Here
    Visit Here
    Visit Here

    ReplyDelete
  48. The blog was absolutely fantastic! Lot of great information which can be helpful in some or the other way. Keep updating the blog, looking forward for more contents.

    Online Doctor Consultation Uk

    ReplyDelete
  49. This comment has been removed by the author.

    ReplyDelete

  50. India's pharmaceutical sector is a global leader, supplying over 50% of vaccines and 40% of generics in the US. With a compound annual growth rate of 3−6%, the global pharmaceutical market is set to exceed $1.5 trillion by 2023. The industry's focus on biosimilars, generics, and OTC drugs is evident, with an anticipated three-fold increase in biosimilar competition by 2023. Changing landscapes foresee consolidation, technology transfer, and a shift towards "vocal for local." Challenges include a more competitive IP landscape, pricing pressures, and reimbursement restrictions. Companies are adapting with a focus on novel therapies, automation, and embracing technology for growth.





    ReplyDelete

Post a Comment

Most Favorite Reads!

Ethanol - Demand, Production, Opportunities & Production Projections (Part-2)

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-2)

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-1)

Nutraceuticals - The Next Gem of Healthcare Sector

Laurus Labs - Result Update Q4FY21 & Full Year FY21